Retatrutide
A triple GLP-1/GIP/glucagon agonist in clinical trials. Phase 2 reported up to -24.2% body weight at 48 weeks.
Calorize — peptide protocol & nutrition tracker
This substance is still in clinical trials and is not approved for use as a medicine in any country. The figures below come from published trial protocols; they describe what was studied, not what you should take.
Every figure on this page is a dose reported in published sources. It is reference information, not a recommendation and not a protocol to follow. Any decision about injecting is one to make with a doctor.
Medical disclaimerWhat is Retatrutide?
A triple agonist of the GLP-1, GIP and glucagon receptors, developed by Eli Lilly. No regulator has approved it: the compound is in clinical trials.
Unlike most of this catalogue, the figures here are not from forums but from a peer-reviewed publication. The phase 2 trial published in the New England Journal of Medicine reported weight reduction of 22.8% at 8 mg and 24.2% at 12 mg by week 48.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
Rapid weight loss burns muscle along with fat — that is what sits behind Ozempic face. Enough protein is what separates the two.
Check Protein Norm